KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Long-Term Investments (2016 - 2025)

Bio-Rad Laboratories (BIO) has disclosed Long-Term Investments for 14 consecutive years, with $6.1 billion as the latest value for Q4 2025.

  • On a quarterly basis, Long-Term Investments rose 26.13% to $6.1 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $6.1 billion, a 26.13% increase, with the full-year FY2025 number at $6.1 billion, up 26.13% from a year prior.
  • Long-Term Investments was $6.1 billion for Q4 2025 at Bio-Rad Laboratories, up from $5.1 billion in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $16.2 billion in Q3 2021 to a low of $4.8 billion in Q4 2024.
  • A 5-year average of $8.3 billion and a median of $7.6 billion in 2022 define the central range for Long-Term Investments.
  • Peak YoY movement for Long-Term Investments: skyrocketed 93.26% in 2021, then plummeted 54.04% in 2022.
  • Bio-Rad Laboratories' Long-Term Investments stood at $14.4 billion in 2021, then tumbled by 38.62% to $8.8 billion in 2022, then fell by 12.83% to $7.7 billion in 2023, then crashed by 37.14% to $4.8 billion in 2024, then rose by 26.13% to $6.1 billion in 2025.
  • Per Business Quant, the three most recent readings for BIO's Long-Term Investments are $6.1 billion (Q4 2025), $5.1 billion (Q3 2025), and $5.6 billion (Q2 2025).